Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Phase II trial of heat shock protein inhibitor for metastatic breast cancer initiated
January 19th, 2006
Kosan Biosciences Incorporated (KOSN) announced the initiation of a phase II clinical trial in patients with HER2-positive metastatic breast cancer, administering KOS-953, the company's proprietary formulation of the heat shock protein 90 (Hsp90) inhibitor 17-AAG, in combination with trastuzumab (Herceptin). Interim data from the phase Ib dose-escalating clinical trial using this combination was presented at the 28th Annual San Antonio Breast Cancer Symposium. The phase Ib dose-escalating and phase II clinical trials of KOS-953 in combination with trastuzumab are being conducted at Memorial Sloan-Kettering Cancer Center and Arizona Cancer Center. The...
Source: Women's Health Weekly (2006-01-19)
|
